Nandec-50 Injection 1 ml belongs to the group of medications called ‘anabolic steroids’ used to treat osteoporosis in post-menopausal women. Osteoporosis is a medical condition in which bone becomes thin or weak. When a woman reaches menopause stage, ovaries stop making estrogen, a female hormone responsible for bone health. Due to the deficiency of estrogen, inadequate bone formation occurs, resulting in the weakening of bones. The earlier a woman reaches to her menopause, the more the chances of osteoporosis. This condition can result in brittle or broken bones if prompt treatment is not given.

Nandec-50 Injection 1 ml contains ‘Nandrolone’ which is a steroid used to prevent bone loss. It works by inhibiting bone resorption (breaking down of bone tissue) and promote bone formation. It can effectively delay bone loss.

The common side-effects of Nandec-50 Injection 1 ml are fluid retention in the tissues (swelling of the ankles or feet or increased blood pressure), masculinization (an increase in male characteristics in women) such as a change in voice, hoarseness, increase in body or facial hair or acne, increased libido (sexual desire), nausea and itching. It may also alter blood tests such as increased haemoglobin levels, changes in blood lipids (fats) and liver function tests. Inform your doctor if any of these side-effects persist or worsen.

Do not take Nandec-50 Injection 1 ml if you are allergic to ‘Nandrolone’ or any ingredients such as Arachis oil or peanut oil and benzyl alcohol present in it. It should not be given in conditions such as breast cancer in women with hypercalcemia (high calcium levels in the body), diagnosed or suspected breast cancer in men, kidney diseases and diagnosed or suspected prostate cancer. It should not be used in pregnant or breastfeeding women.

Nandec-50 Injection 1 ml contains 'nandrolone' which is an anabolic steroid. It can effectively treat osteoporosis in postmenopausal women, especially in women with a lean body or muscle mass. It works by inhibiting the breakdown of bone tissue and promoting bone formation. It also increases muscle mass in the body.

Nandec-50 Injection 1 ml may alter haemoglobin levels, so regular monitoring of patients should be required at least once in 3 months in the initial 12 months followed by once in a year till the completion of therapy. Elderly patients should be monitored for calcium levels and the presence of tumours. In patients with heart, kidney, liver diseases, epilepsy (fits), and migraine, there is a risk of oedema or fluid retention. In such cases, treatment should be discontinued immediately.